BioInvent International
38.5
SEK
-1.03 %
BINV
NASDAQ Stockholm
Biotechnology & Pharmaceuticals
Health Care
2 following
-1.03%
-10.47%
-20.21%
+2.39%
+103.06%
+103.06%
-16.16%
+30.84%
-95.96%
BioInvent International is active in the pharmaceutical industry. The company focuses on the research and development of antibody drugs used in the treatment of cancer. The company has its own development platform and collaborations take place via the company's partners. In the early development phase, the company is working to recreate the disease biology to get indications about the substance's effect on the disease. The head office is located in Lund, Sweden.
Read moreMarket cap
2.53B SEK
Turnover
1.61M SEK
Revenue
71.46M
EBIT %
-517.69 %
P/E
-
Dividend yield-%
-
Financial calendar
27/2
2025
Annual report '24
29/4
2025
Interim report Q1'25
29/4
2025
General meeting '24
ShowingAll content types
BioInvent International AB: BioStock: US expansion in focus as BioInvent welcomes new SVP
BioInvent meddelar att första patienten rekryterats till fas 1b/2a-studien med BI-1607 i kombination med ipilimumab och KEYTRUDA (pembrolizumab) i patienter med inoperabelt eller metastaserat melanom
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools